miRNA Sequencing and Assay Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

The publisher unveils insights into the thriving miRNA Sequencing and Assay Market

The publisher has released its latest report on the miRNA Sequencing and Assay Market, showcasing remarkable growth potential and factors driving its expansion. In 2024, the global market reached US$343 million in sales, and the market is set to scale new heights.

Sequencing by Synthesis Takes the Lead

Sequencing by Synthesis is anticipated to be the highest revenue-generating technology category from 2024 to 2031. This highlights the critical role of technological advancements in driving the miRNA Sequencing and Assay Market forward.

Driving Forces for miRNA Sequencing and Assay Demand

The market's growth is propelled by several key factors, including:

1. Increase in Infectious and Communicable Illnesses: A surge in the frequency of infectious diseases has intensified the need for accurate miRNA sequencing and assays for diagnosis and treatment.

2. Technological Advancements: Ongoing technological innovations have opened new avenues for extracting miRNA sequences efficiently, enhancing the overall market prospects.

3. Interest in miRNA Biomarker Identification: The growing interest in identifying miRNA biomarkers for various medical conditions is driving demand in the miRNA sequencing and testing sector.

4. Rising Neurological Illnesses: With an uptick in neurological disorders, the demand for personalized treatments and precise diagnostics has driven the growth of this market segment.

North America Dominates the Market

North America is expected to offer the largest opportunity for the miRNA Sequencing and Assay Market, accounting for over 4% of the market share throughout the forecasted period. The region's dominance can be attributed to the presence of prominent firms like Illumina Inc., PerkinElmer, Inc., and Thermo Fisher Scientific, which have significantly increased their R&D expenditure to develop novel solutions. Illumina, Inc., for instance, allocated US$682 million for research and development in 2020, underscoring its commitment to advancing sequence analysis technologies.

Asia Pacific Emerges as the Fastest-Growing Region

The Asia Pacific region is projected to witness the fastest growth in the miRNA Sequencing and Assay Market throughout the forecast period. This growth can be attributed to the presence of organizations such as APBioNet, which actively supports and educates researchers in the field. APBioNet plays a pivotal role in tracking the development of bioinformatics infrastructure, facilitating data sharing, and hosting training programs, seminars, and conferences, thus driving the rapid growth of the miRNA Sequencing and Assay Market in the region.

Covid-19 Impact on the Market

The Covid-19 pandemic brought new insights into the miRNA Sequencing and Assay Market as researchers discovered the interaction between SARS-CoV-2 RNA sequences and human MicroRNAs during vaccine development. This revelation highlighted the critical role of miRNAs in virus-host cell interactions. As a result, the market saw increased interest in understanding how host miRNAs influence SARS-CoV-2 infection.

Country-wise Analysis

U.S. miRNA Sequencing and Assay Market Analysis

The United States is poised to dominate the miRNA Sequencing and Assay Market, holding the highest market share by the end of 2031. The growth in this market can be attributed to increased investments in sequencing development, expanding research efforts in the fields of Genomics and RNA biology, and a growing demand for cost-effective, high-throughput approaches for miRNA analysis.

U.K. miRNA Sequencing and Assay Market Analysis

The miRNA Sequencing and Assay Market in the United Kingdom (U.K.) is on a trajectory to reach a substantial valuation in 2031, having grown significantly from its 2024 figure. During the forecast period, the market is expected to present a noteworthy dollar opportunity, highlighting its potential for substantial growth.

Japan miRNA Sequencing and Assay Market Analysis

Japan is witnessing substantial growth in its miRNA Sequencing and Assay Market, with an expected increase in valuation from 2023. With a promising compound annual growth rate (CAGR), the Japanese market is set to offer a considerable absolute dollar opportunity during the forecast period, indicating a robust growth trajectory.

South Korea miRNA Sequencing and Assay Market Analysis

The miRNA Sequencing and Assay Market in South Korea is experiencing significant expansion, with a notable rise in valuation since 2023. This market is projected to maintain its growth momentum with a respectable CAGR, offering a substantial absolute dollar opportunity during the forecast period, reflecting its potential for sustained development.

Competitive Landscape

Key companies operating in the miRNA Sequencing and Assay Market include Thermo Fisher Scientific, Illumina, QIAGEN, PerkinElmer, Abcam plc, New England Biolabs, Takara Bio Inc., Lexogen GmbH, Norgen Biotek Corp, Maravai LifeSciences, HTG Molecular Diagnostics, Meridian Bioscience, Inc., and System Biosciences, LLC. These industry leaders continue to drive innovation and shape the future of miRNA sequencing and assays.

Market Segments Covered in miRNA Sequencing and Assay Market Analysis

By Component

• Products
• Library Preparation Kits
• Sequencing Consumables
• Instruments
• Services

By Technology

• Sequencing by Synthesis
• Seq. by Oligonucleotide Ligation and Detection (SOLiD)
• Nanopore Seq.
• Sanger Seq.
• Single Molecule Real-time (SMRT) Seq.

By Workflow

• Library Preparation
• Sequencing
• Data Analysis & Storage

By Application

• Cancer
• Polyglutamine Diseases
• Autoimmune Disease
• Schizophrenia
• Other Applications

By Region

• North America
• Europe
• Asia Pacific
• Middle East and Africa
• Latin America

This product will be delivered within 1-3 business days.